Published in Nat Rev Nephrol on September 01, 2010
Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med (2015) 0.94
Risk of bladder cancer in renal transplant recipients: a meta-analysis. Br J Cancer (2014) 0.90
Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility. J Biol Chem (2013) 0.87
Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J Clin Immunol (2011) 0.85
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol (2011) 0.83
Tumor site immune markers associated with risk for subsequent basal cell carcinomas. PLoS One (2011) 0.80
Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nat Rev Nephrol (2016) 0.80
Prevalence of advanced colorectal neoplasm after kidney transplantation: surveillance based on the results of screening colonoscopy. Dig Dis Sci (2015) 0.77
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. Biomed Res Int (2015) 0.75
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant (2016) 0.75
Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia. J Korean Med Sci (2012) 0.75
Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy? J Ophthalmic Inflamm Infect (2013) 0.75
Hepatocellular carcinoma following renal transplantation. Gastrointest Cancer Res (2011) 0.75
Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. World J Urol (2015) 0.75
Transperitoneal laparoscopic nephroureterectomy for native upper tract urothelial carcinoma in renal transplant recipients. World J Urol (2012) 0.75
Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med (1999) 15.69
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA (2005) 5.52
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08
Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet (1999) 4.04
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77
Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet (2002) 3.68
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet (2004) 3.38
Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell (2002) 3.35
Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol (2000) 3.30
Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant (2004) 3.25
Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med (1998) 3.21
Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol (2002) 3.20
Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol (1999) 3.19
Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA (1993) 3.10
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature (1998) 2.76
Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64
Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med (2003) 2.61
Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci U S A (1997) 2.50
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet (1995) 2.50
Merkel's cell carcinoma in organ recipients: report of 41 cases. Transplantation (1999) 2.47
A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest (2001) 2.36
The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol (1995) 2.32
Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). J Virol (2001) 2.31
The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int (2007) 2.10
Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol (1998) 2.01
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A (1997) 1.98
Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 1.94
Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology (2000) 1.93
The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88
Cancer risk in patients on dialysis and after renal transplantation. Lancet (2000) 1.87
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int (2003) 1.83
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation (2010) 1.83
Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med (1998) 1.80
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2003) 1.70
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol (2001) 1.68
Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant (2008) 1.65
Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrol Dial Transplant (2007) 1.63
Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation (2005) 1.62
Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer (1986) 1.58
Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation (2000) 1.58
Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J Virol (2000) 1.57
Cancers complicating organ transplantation. N Engl J Med (1990) 1.57
Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol (2005) 1.54
Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation (2007) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant (2004) 1.50
The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int (2005) 1.46
Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res (2003) 1.46
Causes of death after renal transplantation. Nephrol Dial Transplant (2001) 1.45
Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol (2001) 1.40
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation (2004) 1.39
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant (2005) 1.33
Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation (2006) 1.29
Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol (2000) 1.29
Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer (2005) 1.29
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A (2000) 1.27
Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ (2005) 1.26
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation (2009) 1.25
Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis (2000) 1.24
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood (2009) 1.23
Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation (2009) 1.22
Malignant melanoma in organ allograft recipients. Transplantation (1996) 1.22
Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis (1994) 1.16
Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation (2003) 1.16
Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc (1997) 1.14
Incidence of cancer after kidney transplant: results from the North Italy transplant program. Transplantation (2003) 1.14
Donor transmitted malignancies. Ann Transplant (2004) 1.13
Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract (1998) 1.11
Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol (2000) 1.10
The effect of immunosuppression on pre-existing cancers. Transplantation (1993) 1.08
Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol (1998) 1.06
Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation (2008) 1.06
Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant (2007) 1.04
The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation (2009) 1.04
Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant (2007) 1.03
The changing causes of graft loss and death after kidney transplantation. Transplantation (2002) 1.02
Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant (1994) 1.02
A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol (2003) 1.01
Primary lung carcinoma after heart or lung transplantation: management and outcome. J Thorac Cardiovasc Surg (2002) 1.00
Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol (1995) 0.98
Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg (2004) 0.97
Minimizing the risk of posttransplant malignancy. Transplantation (2009) 0.97
Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol (2001) 0.97
Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation. Medicine (Baltimore) (2005) 0.96
Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation (2003) 0.96
Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant (2002) 0.95
Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant (1996) 0.95
Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med (2007) 9.44
Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol (2006) 1.79
CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood (2008) 1.56
Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int (2013) 1.54
Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation (2012) 1.52
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation. Transplantation (2009) 1.44
Accuracy and variability of equations to estimate glomerular filtration rates in renal transplant patients receiving sirolimus and/or calcineurin inhibitor immunosuppression. Transpl Int (2008) 1.37
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia (2013) 1.37
Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol (2008) 1.15
Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev (2012) 1.11
Estimation of total glomerular number in stable renal transplants. J Am Soc Nephrol (2003) 1.10
Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J (2002) 1.10
Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol (2007) 1.08
Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol (2008) 1.04
Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int (2002) 0.99
Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant (2009) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes (2004) 0.94
CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms. PLoS One (2013) 0.93
Belatacept: from rational design to clinical application. Transpl Int (2011) 0.93
Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials. Transplantation (2013) 0.93
Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int (2011) 0.92
Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant (2007) 0.90
Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant (2008) 0.90
Renal involvement in non-malignant IgM gammopathy. Nephrol Dial Transplant (2006) 0.89
RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood (2004) 0.89
Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrol Dial Transplant (2011) 0.87
Biomarkers in renal transplantation. Curr Opin Organ Transplant (2010) 0.87
Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int (2012) 0.86
Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation (2004) 0.86
Resistive index and chronic allograft nephropathy evaluated in protocol biopsies as predictors of graft outcome. Nephrol Dial Transplant (2005) 0.84
Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation (2004) 0.83
The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci (2010) 0.83
Kidney regeneration and repair after transplantation. Curr Opin Organ Transplant (2013) 0.82
Reduction of postischemic immune inflammatory response: an effective strategy for attenuating chronic allograft nephropathy. Transplantation (2005) 0.82
Intragraft expression of the IL-10 gene is up-regulated in renal protocol biopsies with early interstitial fibrosis, tubular atrophy, and subclinical rejection. Am J Pathol (2010) 0.82
IgA nephropathy recurs early in the graft when assessed by protocol biopsy. Nephrol Dial Transplant (2011) 0.82
The renin angiotensin system blockade in kidney transplantation: pros and cons. Transpl Int (2008) 0.81
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation (2005) 0.81
Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. Nephrol Dial Transplant (2011) 0.81
Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant (2011) 0.81
Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN. Ther Drug Monit (2014) 0.80
Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant (2006) 0.80
Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant (2003) 0.80
Early hematopoietic microchimerism predicts clinical outcome after kidney transplantation. Transplantation (2007) 0.80
Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies. Contrib Nephrol (2008) 0.79
Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation. Transpl Int (2014) 0.79
Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function. J Pharm Pharm Sci (2012) 0.79
Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. Transplantation (2007) 0.79
Glomerular enlargement assessed by paired donor and early protocol renal allograft biopsies. Am J Transplant (2004) 0.78
New immunosuppressive protocols with the advent of novel biological drugs. Transplantation (2009) 0.78
Intramuscular SP1017-formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues. J Gene Med (2004) 0.78
Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm. Transpl Int (2014) 0.78
Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia (2012) 0.77
Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib Nephrol (2012) 0.77
Inhibitors of the mammalian target of rapamycin and transplant tolerance. Transplantation (2009) 0.77
Relationship between subclinical rejection and genotype, renal messenger RNA, and plasma protein transforming growth factor-beta1 levels. Transplantation (2006) 0.77
Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation (2010) 0.76
Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability? Drugs (2006) 0.76
Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit (2015) 0.76
New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic. Immunotherapy (2013) 0.76
Steroids can be safely withdrawn from cyclosporine and mycophenolate mofetil-treated renal allograft recipients: long-term results. Transplantation (2005) 0.75
Acute renal failure associated to renin angiotensin system (RAS) inhibitors--its burden in a nephrology department. Nephrol Dial Transplant (2007) 0.75
Acute renal failure induced by acute interstitial nephritis secondary to cocaine. Nefrologia (2013) 0.75
Steroid sparing strategies in renal transplantation. Nephrol Dial Transplant (2005) 0.75
Subclinical rejection and sirolimus associated edema in renal allograft recipients. Transpl Int (2007) 0.75
Cold ischaemia, innate immunity and deterioration of the glomerular filtration barrier in antibody-mediated acute rejection. Nephrol Dial Transplant (2012) 0.75
Pretransplant low CD3+CD25high cell counts or a low CD3+CD25high/CD3+HLA-DR+ ratio are associated with an increased risk to acute renal allograft rejection. Transplantation (2011) 0.75
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenet Genomics (2017) 0.75
Different storing and processing conditions of human lymphocytes do not alter P-glycoprotein rhodamine 123 efflux. J Pharm Pharm Sci (2009) 0.75
Structural and functional correlations in stable renal allografts. Am J Kidney Dis (2003) 0.75
Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus. Transplantation (2008) 0.75
Once-monthly pegylated epoetin Beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation (2013) 0.75